ニューロウジェネスィス
Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.53 | $0 | -$24M |
| 2026 Q1 | -1.39 | $0 | -$26M |
| 2025 Q4 | -1.60 | $0 | -$17M |
| 2025 Q3 | -0.99 | $0 | -$20M |
| 2025 Q2 | -1.05 | $0 | -$20M |
| 2025 Q1 | -1.08 | $0 | -$22M |
| 2024 Q4 |
| -1.31 |
| $0 |
| -$18M |
| 2024 Q3 | -1.19 | $0 | -$16M |